CorneaGen
Thomas Frinzi is the former Worldwide President, Surgical, Johnson & Johnson Vision business, which includes a broad ophthalmology portfolio across the areas of cataracts and refractive surgery (LASIK). Tom was appointed to his position in February 2017 at the conclusion of Johnson & Johnson’s acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. Mr. Frinzi joined AMO in January 2016 as Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics.
Prior to joining Abbott, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. Most recently, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Johnson & Johnson. In recognition of his leadership, expertise and vision in the field, Mr. Frinzi was awarded the 2015 Ophthalmology Innovation Award by the Ophthalmology Innovation Summit. He earned a bachelor’s degree in political science from the University of Tampa.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
CorneaGen
1 followers
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.